HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Welch Leads US FDA’s Dietary Supplement Office

Executive Summary

Center for Food Safety and Applied Nutrition says Cara Welch selected to fill Office of Dietary Supplement Programs director post. She’ll move up from ODSP deputy director on 14 March.

You may also be interested in...



The Dietary Supplement Market US FDA Is Regulating Isn’t Your 1994 DSHEA Version

“In the last 30 years, we've seen this sort of explosion, and it's not just more products and more sales. We're talking about more complex products,” says Cara Welch, FDA Office of Dietary Supplement Programs director. “Today's products are not the products from 1994.”

With Mandatory Product Listing, FDA Not Looking For Gate To Open Or Close On Supplements

Mandatory product listings would help FDA eliminate gap of missing NDI notifications it expects haven't been filed and other information about ingredients but not establish pre-market approval tool.

NDI Notifications For CBD ‘Excluded’ On Arrival But US FDA Still Explains Where Safety Evidence Fails

CFSAN Office of Dietary Supplement Programs tells Charlotte’s Web and Irwin Naturals that not providing sufficient evidence of a reasonable assumption of safety for an NDI's intended use wasn’t the only reason each notification was rejected.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS152294

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel